XML 49 R34.htm IDEA: XBRL DOCUMENT

Share-Based Payment

12 Months Ended

Dec. 31, 2024

26.	SHARE-BASED PAYMENT

See accounting policy in Note 2.3.15.

26.1 Cash-settled share-based payment transactions

Participants are subject to meeting corporate performance targets and service conditions to acquire the right.

Below, the position of outstanding shares granted:


													12.31.2023				12.31.2024
Date of grants	Date of acquisition of rights (i)		Fair value at date of grant R$ (ii)		Quantity granted		(-) Quantity canceled and other adjustments			(-) Quantity paid or advanced			(=) Total of shares		Fair value of liability - US$ (iii)		Quantity granted		(-) Quantity canceled and other adjustments			(-) Quantity paid or advanced			(=) Total of shares		Fair value of liability - US$ (iii)
03.12.2019		03.12.2024		19.30		1,349,153		(238,777	)		(945,407	)		164,969		0.8		—		—			(164,969	)		—		—
03.24.2020		03.24.2025		16.95		1,633,741		(516,702	)		(775,825	)		341,214		1.4		—		(1,404	)		(168,061	)		171,749		1.5
03.18.2021		03.18.2024		11.29		2,181,442		(221,420	)		—			1,960,022		9.0		—		—			(1,960,022	)		—		—
03.11.2022		03.11.2025		17.61		2,292,434		(253,350	)		—			2,039,084		6.1		—		—			—			2,039,084		17.3
09.05.2022		09.05.2027		13.69		13,621,919		(10,544	)		(2,722,275	)		10,889,100		9.9		—		—			(2,722,275	)		8,166,825		45.6
11.18.2022		11.18.2026		12.58		4,494,033		36,415			(906,090	)		3,624,358		4.0		—		—			(906,090	)		2,718,268		18.6
03.09.2023		03.09.2026		16.35		3,471,772		(112,750	)		—			3,359,022		4.5		—		—			—			3,359,022		18.6
09.13.2023		09.13.2027		18.55		1,802,095		(30,335	)		—			1,771,760		0.7		—		(9,935	)		(352,366	)		1,409,459		4.3
08.02.2024		08.02.2028		22.43		—		—			—			—		—		4,088,971		(99,386	)		—			3,989,585		8.3
03.14.2024		03.14.2027		22.95		—		—			—			—		—		2,537,146		—			—			2,537,146		6.4

				Total		30,846,589		(1,347,463	)		(5,349,597	)		24,149,529		36.4		6,626,117		(110,725	)		(6,273,783	)		24,391,138		120.6

(i)	Generally, the settlement of granted plans occurs on the date of acquisition of rights. Advances are made on an exceptional basis on each anniversary of the grant date for some plans.

(ii)	Refers to the fair value on the grant date. The fair value of the share on the grant date is determined based on the average price of the last 30 trading sessions of the EMBR3 share on B3.

(iii)

The fair value of the share used to measure the fair value of the liability is determined based on the average price of the last 10 trading sessions of the EMBR share on B3. When applicable, dividends effectively distributed, including interest on equity, are added to the fair value of the share. This amount added to the applicable labor charges is presented as accounts payable (Note 21).

26.2 Equity-settled share-based payment transactions

In this Note, the values relating to the share prices are presented in units of US$.

These plans are granted to employees of Eve Holding and its subsidiaries. The acquisition of the right to receive shares (NYSE: EVEX) is subject to the fulfillment of performance targets, which may include market conditions, and service conditions (from 2 to 5 years).

The fair value of the share on the date of grant is the market price of the share observed on the date of grant, except for plans that include market conditions. In these cases, the Monte Carlo simulation is used to estimate the fair value of the share at grant date.

As of December 31, 2024, the number of shares granted without market conditions is 1,972,220 (2023: 555,654), with an average price on the grant date of US$7.30 (2023: US$8.37) and an average remaining term of 2.3 years (2023: 1.5 years). On this date, the number of shares granted with market conditions is 526,830 (2023: 576,682), with an average price on the grant date of US$12.53 (2023: US$13.98) and an average remaining term of 2.8 years (2023: 3.8 years).

The amount recognized in equity is US$ 11.9 (2023: US$ 7.4).